Search Results

Displaying Results 1-12 of 12 "'ASTR'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene

Aug 28, 2026, 07:00 ET CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene

[email protected] Investor Contact:Brian KorbAstr [email protected]+1 (917) 653-5122 

More news about: CREATE Medicines, Inc.

CREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash University

Jul 31, 2026, 07:00 ET CREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash University

[email protected] CREATE Investor Contact:Brian KorbAstr [email protected]+1 (917) 653-5122Monash

More news about: CREATE Medicines, Inc.

CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases

Jul 30, 2026, 07:00 ET CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases

[email protected] Contact: Brian KorbAstr [email protected]+1 (917) 653-5122

More news about: CREATE Medicines, Inc.

CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD

May 14, 2026, 08:10 ET CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD

[email protected] Contact:Brian KorbAstr [email protected] +1 (917) 653-5122

More news about: CREATE Medicines, Inc.

CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology

May 14, 2026, 08:00 ET CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology

[email protected] Contact:Brian KorbAstr [email protected]+1 (917) 653-5122

More news about: CREATE Medicines, Inc.

Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87

May 07, 2026, 20:30 ET Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87

[email protected]+86 571-8630-9565Astr PartnersBob [email protected]+1 646-389-6658

More news about: Chance Pharmaceuticals

CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform

Feb 02, 2026, 16:00 ET CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform

[email protected] Contact: Brian Korb | Astr Partners | [email protected] | +1 (917) 653-5122

More news about: CREATE Medicines, Inc.

CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 08, 2026, 16:00 ET CREATE Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

[email protected] Contact: Brian Korb | Astr Partners | [email protected] | +1 (917) 653-5122

More news about: CREATE Medicines, Inc.

CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy

Dec 09, 2025, 08:00 ET CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy

[email protected] Contact:Brian KorbAstr [email protected] | +1 (917) 653-5122

More news about: CREATE Medicines, Inc.

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 29, 2025, 08:00 ET Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

[email protected] astr partnersMatthew [email protected]

More news about: Coya Therapeutics, Inc.

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 22, 2025, 08:00 ET Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

David Snyder, [email protected] astr partnersMatthew [email protected]

More news about: Coya Therapeutics, Inc.

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 16, 2025, 08:00 ET Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Contact David Snyder, [email protected] astr partnersMatthew [email protected]

More news about: Coya Therapeutics, Inc.

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.